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Poster Session II S319February 2009, 33 pts received CI CsA during their allogeneic
HSCT. Thirteen of these pts weighed$ 50 kg: 9 were males, the
median age was 16 years (11-18 years) and the mean weight was
66.3 kg (51.7 – 88 kg). Seven of 13 pts received dosa-
ges. 250 mg/day based on weight (6 of whom received 5 mg/kg/
day and 1 received  4 mg/kg/day (300 mg/day). Six pts received
dosages# 250 mg (5 of whom received 250 mg/day and 1 received
200 mg/day). After initial steady state, the median CsA level was
436 ng/ml (220-806, Mass-spectrometry). Toxicities that required
dose adjustment include: Hypertension (n5 5) Hyperbilirubinemia
(n5 3), increase in BUN/Cr (n5 1). 71% of pts$ 50 kg who re-
ceived weight based doses. 250 mg/day required a dose reduction
by the fifth day of therapy while none of the pts$ 50 kg receiving
doses# 250 mg/day needed dose adjustments (p5 0.02, Fisher’s
Exact Test). Two pts who received .250 mg/day dosage and did
not have a dose reduction in the first five days of therapy required
a dose reduction within 10 days of initiation of CsA due to toxicity.
No patients receiving the 250 mg maximum dose required an in-
crease above 250 mg in the first 5 days of therapy or dose adjust-
ment due to toxicity. This data supports the implementation of
a 250 mg/day maximum dosage of CI CsA for patients who
weigh$ 50 kg.Multivariable Logistic Regression Model for acute GVHD
Outcome
Variable OR 95% CI P
MTX vs. Siro 4.47 1.33-15 0.015
Age 0.894 0.95-1.04 NS
Female vs. Male 0.258 0.2-1.53 NS
MUD vs. MRD 0.842 0.36-3.49 NS
Acute Leukemia vs. Other 0.212 0.64-6.99 NS
Donor CMV positive 0.724 0.29-2.36 NS
Recipient CMV positive 0.008 1.5-14.4 0.008
PBSC vs. BM 0.159 0.71-7.85 NS
ATG 0.568 0.11-3.25 NS441
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Polyoma virus reactivation and related cystitis in patients under-
going allogeneic hematopoietic stem cell transplant (alloHSCT) is
associated with significant morbidity. We conducted a retrospec-
tive review of 604 patients undergoing alloHSCT at Duke Univer-
sity Medical Center between Jan 1995 to Dec 2008. Polyoma virus
screening was performed on urine samples using electron micros-
copy (EM). EM screening was performed on 192 (32%) patients
with cystitis symptoms (dysuria, urgency, hesitancy, hemorrhage,
frequency). EM screened patients were evaluated for incidence
of polyoma infection, duration of symptoms, hemorrhagic cystitis,
and possible risk factors. Logistic regression modeling was used to
predict EM positivity in the 192 patients with symptomatic cysti-
tis. Pearson’s Chi-Square test was used to compare differences in
proportions. Of 192 patients screened, 96 (50%) tested positive
for polyoma virus. The median time to EM positivity was 1.38
months (n5 88). The median duration of symptoms in the EM
positive group was 1 month (range 15 days – 1 year), compared
to 15 days (range 15 days – 3 months) in the EM negative group.
Patients with symptomatic cystitis undergoing an alemtuzumab-
containing non-myeloablative transplantation (NMAT) had
a higher incidence of polyoma infection compared to standard
myeloablative alloHSCT (62% vs. 32%, Chi sq p\0.001). In
a subgroup analysis of NMAT patients, comparing regimen inten-
sity (Fludarabine/Cyclophosphamide 2 g/m2 vs. Fludarabine/Mel-
phalan 140 mg/m2 or Busulfan 260 mg/m2), no difference in the
incidence of polyoma infection was detected (67% vs 74%, Chi-
sq p5 0.497). This indicates that T-cell depletion has a greater
impact than regimen intensity on the development of polyoma in-
fection. Patients who received transplantation from a haploidenti-
cal donor were at greatest risk for developing polyoma infection
(Chi-sq p5 0.041). We found no difference in polyoma infection
rates based on the severity of graft vs. host disease. Ciprofloxacin
use did not attenuate the incidence of polyoma infection. A mul-
tivariate regression analysis identified alemtuzumab-containing
NMAT, haploidentical donor, and concurrent CMV infection as
risk factors for the development of polyoma infection. We con-
clude that polyoma virus was the predominant source of cystitis
in patient undergoing an alemtuzumab-containing NMAT. In
contrast to other published reports, regimen intensity is not
a major factor.442
SIROLIMUS COMPARED TO METHOTREXATE BASED IMMUNOSUPPRES-
SION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN AL-
LOGENEIC STEM CELL TRANSPLANTATION: A SINGLE INSTITUTION
EXPERIENCE
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Methotrexate (MTX) is a standard agent used in combination
with calcineurin inhibitors for GvHD prophylaxis in patients un-
dergoing an allogeneic hematopoeitic stem cell transplant
(HCT). We compared the incidence of acute GvHD following
allogeneic transplantation using the combination of sirolimus
(siro) and tacrolimus (tacro) to MTX plus either tacro or cyclo-
sporine.
Between January 1, 2005 and April 30, 2009, 106 consecutive
patients who received allogeneic bone marrow or peripheral blood
stem cell (PBSC) transplantation using a myeloablative regimen
for hematological malignancies were evaluated. Patients were
included if they were. 18 years old, and matched at least at HLA-
A, -B, and DRB1 by high-resolution typing. Patients receiving
reduced-intensity or cord blood transplantation were excluded.
The primary endpoint was the incidence and severity of acute
GvHD. Secondary endpoints included chronic GvHD, incidence
of venoocclusive disease (VOD), thrombotic microangiopathy
(TMA), interstitial pneumonitis (IP).
The median (range) age for the siro (n5 59) and MTX (n5 47)
groups were 44 (21-59) and 39 years (20-57), respectively. Of pa-
tients receiving MTX, 33 (70%) also received cyclosporine and 14
(30%) tacro. Thirty-four (57%) patients in the siro group and 19
(40%) in the MTX group received stem cells from matched unre-
lated donors (MUD). Forty-seven percent of MUD patients received
antithymocyte globulin (ATG) with siro/tacro.
The incidence of grade II-IV acute GvHD before day +100 was
18.6% in patients receiving siro/tacro, compared to 48.9% receiving
MTX (p5 0.001). The incidence of grade III-IV acute GVHD was
5% and 17% (p5 0.045) for the siro and MTX group, respectively.
The incidence of chronic GvHD was not significantly different be-
tween siro or MTX (32% vs. 38%, p5 0.5). Similarly, there was
no significant difference in the incidence of TMA or IP. However,
VOD occurred in 20% (attributable mortality in 8/12 patients)
who received siro compared to 4% in those receiving MTX (OR
0.103, 95% CI 0.10-1.093, p5 0.059).
This retrospective analysis demonstrated that the combination of
siro and tacro provided more effective acute GvHD prophylaxis
compared to MTX-based immunosupression. Siro was also associ-
ated with an increased incidence of VOD.TRANSPLANT NURSING: ADMINISTRATION
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ASSESSING PATIENT SATISFACTION IN AN OUTPATIENT APHERESIS SET-
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